Professor Cherry Wainwright c.wainwright@rgu.ac.uk
Professor
Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review.
Wainwright, Cherry L.; Teixeira, Mauro M.; Adelson, David L.
Authors
Mauro M. Teixeira
David L. Adelson
Abstract
Drug discovery from natural sources is going through a renaissance, having spent many decades in the shadow of synthetic molecule drug discovery, despite the fact that natural product-derived compounds occupy a much greater chemical space than those created through synthetic chemistry methods. With this new era comes new possibilities, not least the novel targets that have emerged in recent times and the development of state-of-the-art technologies that can be applied to drug discovery from natural sources. Although progress has been made with some immunomodulating drugs, there remains a pressing need for new agents that can be used to treat the wide variety of conditions that arise from disruption, or over-activation, of the immune system; natural products may therefore be key in filling this gap. Recognising that, at present, there is no authoritative article that details the current state-of-the-art of the immunomodulatory activity of natural products, this in-depth review has arisen from a joint effort between the International Union of Basic and Clinical Pharmacology (IUPHAR) Natural Products and Immunopharmacology Sections, with contributions from a number of world-leading researchers in the field of natural product drug discovery, to provide a “position statement” on what natural products has to offer in the search for new immunomodulatory argents. To this end, we provide a historical look at previous discoveries of naturally occurring immunomodulators, present a picture of the current status of the field and provide insight into the future opportunities and challenges for the discovery of new drugs to treat immune-related diseases.
Citation
WAINWRIGHT, C.L., TEIXEIRA, M.M., ADELSON, D.L. et al. 2022. Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review. Pharmacological research [online], 177, article 106076. Available from: https://doi.org/10.1016/j.phrs.2022.106076
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 7, 2022 |
Online Publication Date | Jan 21, 2022 |
Publication Date | Mar 31, 2022 |
Deposit Date | Jan 28, 2022 |
Publicly Available Date | May 23, 2022 |
Journal | Pharmacological research |
Print ISSN | 1043-6618 |
Electronic ISSN | 1096-1186 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 177 |
Article Number | 106076 |
DOI | https://doi.org/10.1016/j.phrs.2022.106076 |
Keywords | Natural products; Immunomodulators; Marine; Venoms and toxins; Metabolomics; Bioinformatics |
Public URL | https://rgu-repository.worktribe.com/output/1580420 |
Related Public URLs | https://rgu-repository.worktribe.com/output/1580420 |
Additional Information | The accompanying file includes supplementary material that is held as separate files on the publisher's website. In this file, the supplementary material appears after the main text. |
Files
WAINWRIGHT 2022 Future directions (VOR)
(10.5 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
GPR55 regulates the responsiveness to, but does not dimerise with, α1A-adrenoceptors.
(2021)
Journal Article
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search